Naveen Pemmaraju: Delighted to be recognized by the Society of Hematologic Oncology for the Honorable Distinction Award

Naveen Pemmaraju, Leukemia Professor at the MD Anderson Cancer Center, shared on his Twitter account:

“Delighted to be recognized by the Society of Hematologic Oncology for the Honorable Distinction Award for work in MPN, BCL-XL, Navitoclax!!! (OD: Addition of Navitoclax to Ruxolitinib for Myelofibrosis Patients With Relapsed/Refractory Disease and Suboptimal Response to Ruxolitinib Montherapy: REFINE Cohort 1 Dose Escalation and Expansion”)

Source: Naveen Pemmaraju / Twitter

Naveen Pemmaraju holds multiple positions at the University of Texas MD Anderson Cancer Center, including Executive Director of Cancer Medicine, the Director of the Leukemia – Cancer Network, and Professor in the Department of Leukemia. He is also the Director of the Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) program at the MDACC Leukemia Department. Dr. Pemmaraju’s clinical/translational research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), myeloproliferative neoplasms (MPN) and acute myeloid Leukemia (AML). Dr. Pemmaraju is also a well-known social media influencer.